Coronavirus

C-SMART trial results presented at ESCMID show a reduction of COVID-19 incidence in cancer patients.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

RedHill Biopharma said it has enrolled its first participant for the study examining the investigational therapy, RHB-107 (upamostat).

Evaluating inpatient mortality for patients without supplemental oxygen at admission across different variants of concern periods with insights from Dr. Andre Kalil.

Monika Pogorzelska-Maziarz, epidemiologist, health services researcher, and associate professor at Thomas Jefferson University, shares insights on COVID-19's influence in acute care hospitals at this year’s Society for Healthcare Epidemiology of America (SHEA) conference.

A large cohort study found this patient group more susceptible to repeat admissions, and points to potential issues associated with ambulatory care.

Comparative analysis of SARS-CoV-2 infection across pediatrics, adults, and older adults.

A small study found physical health problems lingered 1 year after their hospital stay.

New data demonstrates protection against new variants.

In a new federal survey, as many as 3 in 10 US adults have had the condition at some point.

Water sampling reveals COVID-19 trends in homeless populations.

A study evaluates the efficacy of nirmatrelvir-ritonavir in COVID-19 treatment across variants.

Evaluating the importance of RSV vaccination implications for adults.

Emergency use authorization for CorDx TyFast Flu A/B & COVID-19.

This very large study reviewed data, which showed people vaccinated for the virus had a substantial reduction of risk for these types of events.

The company's latest investigational vaccine induced a greater immune response compared to its FDA approved Spikevax product.

Atea Pharmaceuticals bemnifosbuvir aims to help high-risk COVID-19 patients with a new oral option.

A study conducted in China aimed to assess factors such as viral load rebound (VLR), reduction in cycle threshold values, time until VLR, and symptom rebound.

The authorization was given to Invivyd’s pemivibart (Pemgarda), and it is indicated for adults and adolescents with moderate-to-severe immune compromised conditions.

Today serves as a reminder to everyone that there are still no diagnostic tests or FDA-approved treatments for the post-viral condition.

Insights from Jacob Teitelbaum MD on Long COVID Awareness Day.

Saskia Popescu PhD, MPH, MA, FAPIC on understanding the emergence of the origin for future pandemic preparedness, promoting global health security, and addressing long-term health impacts.

A new study shows how correcting misinformation in a certain way can change patients’ attitudes towards vaccination.

A new study examined the association of COVID-19 infection with outpatient care utilization.

A reduced risk of individual symptoms associated with the condition was reported when patients were administered the therapy within 2 days of admittance.

A new study offers some clues into the pathophysiology and biomarkers of post-acute Sequelae of SARS-CoV-2 (PASC).

With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.

Shionogi’s investigational therapy, ensitrelvir, demonstrated a median time-to-symptom resolution of approximately 1 day shorter in the antiviral group versus placebo.

Participants of a recent study who experienced more daily cognitive symptoms had a greater likelihood of reporting moderate interference with functioning, less likelihood of full-time employment, and greater severity of depressive symptoms.